Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.

about

Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.

Item

http://www.wikidata.org/entity/Q47593829

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Categorical improvement in fun ...... s treated with desvenlafaxine.

@en

Categorical improvement in fun ...... s treated with desvenlafaxine.

@nl

type

Item

label

Categorical improvement in fun ...... s treated with desvenlafaxine.

@en

Categorical improvement in fun ...... s treated with desvenlafaxine.

@nl

prefLabel

Categorical improvement in fun ...... s treated with desvenlafaxine.

@en

Categorical improvement in fun ...... s treated with desvenlafaxine.

@nl

P1476

Categorical improvement in fun ...... ts treated with desvenlafaxine

@en

P2093

Claudio N Soares

http://www.w3.org/2001/XMLSchema#string

Matthieu Boucher

http://www.w3.org/2001/XMLSchema#string

Min Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

A new depression scale designed to be sensitive to change

Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale.

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

Unemployment, job retention, and productivity loss among employees with depression

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care.

P304

322-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1017/S1092852917000633

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29140227

http://www.w3.org/2001/XMLSchema#string

P932

6676643

http://www.w3.org/2001/XMLSchema#string